AGP Executive Report
Last update: 12 hours agoFDA Approvals: FDA approved Xocova (ensitrelvir) as the first oral COVID-19 postexposure prophylaxis for adults and adolescents 12+ after contact, using a 5-day regimen and backed by a phase 3 household trial showing a 67% lower risk of symptomatic illness. Oncology Pipeline: Moderna and Merck shared 5-year follow-up data for intismeran autogene plus KEYTRUDA in high-risk resected melanoma, reporting major reductions in recurrence or distant metastasis risk versus KEYTRUDA alone, with exploratory overall survival signals. Healthcare Policy & Payments: The AHA urged CMS not to finalize several FY 2027 payment provisions for inpatient psychiatric, inpatient rehab, and skilled nursing facilities, and CMS issued an interim final rule requiring some Medicaid adults to meet community engagement work hours starting in 2027. AI & Cybersecurity: AHA released a cyber governance guide for secure AI deployment in healthcare, while new reporting highlights physicians seeing widespread non-FDA regulated peptide use. Workforce & Care Quality: Peterson Health and Agape Care Group earned workplace honors for staff support, underscoring ongoing focus on retention in care settings.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
![<![CDATA[The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/8d872c38f749831638ab4b10061cf48065037e1d-1280x804.jpg)
